Shareholders Equity: The sum of preferred and common equity items.
Ovid Therapeutics (OVID) had Shareholders Equity of $130.66M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$7.25M |
|
$-17.41M |
|
-- |
|
$7.25M |
|
$49.69M |
|
$-42.44M |
|
$25.03M |
|
$-17.41M |
|
$-17.41M |
|
$-17.41M |
|
$-17.41M |
|
$-17.41M |
|
$-17.41M |
|
$-42.44M |
|
$-42.17M |
|
73.74M |
|
73.74M |
|
$-0.23 |
|
$-0.23 |
|
| Balance Sheet Financials | |
$74.37M |
|
$0.25M |
|
$76.57M |
|
$150.93M |
|
$8.29M |
|
$11.99M |
|
$11.99M |
|
$20.27M |
|
$130.66M |
|
$130.66M |
|
|
Shareholders Equity |
$130.66M |
130.18M |
|
| Cash Flow Statement Financials | |
$-38.33M |
|
$-49.85M |
|
$75.21M |
|
$28.23M |
|
$15.08M |
|
$-13.15M |
|
$4.81M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.97 |
|
-- |
|
-- |
|
0.08 |
|
0.10 |
|
100.00% |
|
-585.20% |
|
-585.20% |
|
-581.44% |
|
-240.13% |
|
-240.13% |
|
$-38.33M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
-- |
|
-- |
|
-13.33% |
|
-13.33% |
|
-11.54% |
|
-12.21% |
|
$1.00 |
|
$-0.52 |
|
$-0.52 |
|